Corti

Bottom line

Corti is a real-time AI assistant designed to listen during patient encounters and provide triage recommendations, ambient documentation, and clinical decision support. Developed by a Denmark-based vendor, it targets emergency medicine, telemedicine platforms, and ambulance services. The tool aims to reduce documentation burden while flagging critical conditions during the encounter itself. However, adopters should proceed with caution: peer-reviewed evidence validating clinical outcomes is absent, pricing is enterprise-only with no transparency, and clinician sentiment data is too thin to establish real-world performance patterns.

Corti positions itself for high-acuity settings where time-sensitive triage matters most: 911 call centers, emergency departments, and urgent-care telehealth. The vendor claims the system can detect cardiac arrest, sepsis, and stroke during live conversations, though independent validation of these claims is not available in the indexed literature. If your organization already has mature AI governance, strong IT support, and budget flexibility for enterprise pilots, Corti may warrant a proof-of-concept. Solo practices, small groups, and resource-constrained health systems should wait for transparent pricing and published efficacy data before committing.

The pricing model is opaque. The vendor lists only 'Enterprise' tier at zero published cost, signaling that deals are negotiated case-by-case. Expect per-seat annual contracts, implementation fees, and vendor-managed onboarding. Without published case studies or named reference customers in peer-reviewed outlets, buyers must rely on direct vendor conversations and contract pilots to assess fit. This review assigns Corti a provisional rating pending stronger evidence: promising concept, unproven in independent literature, best suited for well-resourced early adopters willing to share implementation learnings with the broader community.

Why we picked it

Corti was not selected as a top pick in any clinical specialty silo for this index, primarily due to the absence of peer-reviewed validation and limited transparency around deployment outcomes. However, the tool merits detailed review because its core promise addresses a legitimate pain point: real-time clinical intelligence layered onto ambient documentation. If the vendor's claims hold under independent scrutiny, Corti could be a differentiated option for emergency and triage workflows where seconds matter and documentation backlogs cripple throughput.

The decision to cover Corti stems from its presence in European emergency-medicine procurement conversations and its positioning as a triage-first AI, rather than a pure documentation scribe. Unlike ambient scribes that passively transcribe and generate notes after the encounter, Corti advertises active listening with live alerts for time-sensitive conditions. This is a higher bar to clear from a safety and liability perspective, and it demands stronger evidence than we currently have access to. Nonetheless, IT leaders and CMIOs evaluating AI for 911 centers, nurse triage lines, or ED intake deserve a clear-eyed assessment of what Corti offers and where its evidence gaps create decision risk.

We include Corti in this index to set a baseline for what constitutes insufficient evidence in clinical AI reviews. Vendors offering real-time decision support without published validation studies, named hospital references, or transparent pricing should expect skeptical buyers. This review is structured to help procurement teams ask the right questions during vendor demos and pilot negotiations, even when public evidence is thin.

What it does well

Corti's stated strength is real-time triage intelligence during live encounters. The system listens to conversations between clinicians and patients, parses symptoms and patient history, and surfaces alerts when it detects patterns consistent with cardiac arrest, stroke, or sepsis. If this functionality performs as advertised, it could reduce diagnostic delays in high-acuity settings where cognitive load and time pressure increase miss rates. Emergency dispatchers and telehealth triage nurses operating under protocol-driven workflows may benefit most, provided the system integrates smoothly with existing call-center or EHR platforms.

The ambient documentation component is table stakes for this product category, but Corti's value proposition hinges on coupling that passive transcription with active decision support. The vendor positions the tool as a copilot that prompts clinicians to ask follow-up questions, suggests differential diagnoses, and flags high-risk presentations in real time. This is conceptually distinct from post-encounter note generation tools like Nuance DAX or Abridge, which do not attempt live clinical reasoning. For organizations seeking both documentation relief and decision augmentation in one platform, Corti's bundled approach may reduce the need for separate point solutions.

Corti's European roots and early adoption in Denmark and the UK suggest familiarity with GDPR compliance and regional healthcare data standards. If the vendor has navigated European regulators successfully, that experience may translate to smoother HIPAA and HITRUST certifications for US adopters. However, this is speculative without published compliance attestations or named US hospital references. Buyers should request current SOC 2 Type II reports, BAA templates, and evidence of FDA clearance if the vendor is marketing the tool as a diagnostic aid rather than administrative software.

Where it falls short

The most glaring weakness is the absence of peer-reviewed evidence validating Corti's clinical claims. A PubMed search returned zero studies evaluating the tool's diagnostic accuracy, false-alert rates, or impact on patient outcomes. The five indexed citations bearing the term 'Corti' refer exclusively to auditory research (cisplatin ototoxicity and hereditary hearing loss), indicating no overlap with the AI tool under review. This evidence vacuum is disqualifying for risk-averse health systems and any organization subject to strict AI validation requirements under emerging regulatory frameworks.

Pricing opacity is the second critical gap. Enterprise-only pricing with no published tiers, per-seat costs, or contract terms means buyers cannot budget or compare Corti against competitors without entering lengthy vendor negotiations. This lack of transparency is common in healthcare AI, but it penalizes smaller organizations that lack procurement leverage and slows adoption cycles. Solo practices, community hospitals, and accountable-care organizations operating on thin margins will find Corti inaccessible until the vendor publishes at least a per-clinician annual-seat cost or a usage-based pricing model.

Clinician sentiment is also missing. Reddit, Doximity, and SERMO discussions indexed for this review yielded zero mentions of Corti, suggesting limited penetration in US physician communities or early-stage market presence. Without real-world user feedback, buyers cannot assess training overhead, alert fatigue, integration friction, or workflow fit. The absence of named hospital case studies in vendor materials or trade press further signals that Corti may still be in pilot or limited-release phases, rather than proven at scale across diverse care settings.

Finally, the tool's triage-first positioning raises liability questions that the vendor has not addressed publicly. If Corti surfaces a real-time alert for cardiac arrest and the clinician dismisses it, who bears responsibility if the diagnosis was correct? Conversely, if the system generates frequent false positives, clinicians may learn to ignore alerts, defeating the tool's core value. These human-factors and medico-legal dynamics require transparent documentation in peer-reviewed studies and clear contractual language around liability indemnification. Buyers should demand explicit answers during procurement.

Deployment realities

Deploying Corti requires technical integration with telephony systems for triage lines or EHR-embedded telehealth platforms for virtual visits. The vendor likely provides API connectors or SIP-trunk integration for call centers, but buyers should confirm which telephony vendors and EHR systems are supported out of the box. Epic, Cerner, and Meditech integrations are baseline expectations for US health systems, but Corti's European origins suggest the vendor may prioritize European EHR platforms first. IT teams should request a detailed integration workbook during vendor evaluation, including data-flow diagrams, HL7 or FHIR endpoint requirements, and expected implementation timelines.

Training overhead is a wildcard. Real-time decision-support tools demand clinician trust, which is earned through transparent alert logic, low false-positive rates, and clear escalation pathways when the AI's recommendation conflicts with clinical judgment. Expect at least two to four hours of initial training per clinician, plus ongoing calibration as the system learns organizational workflows. Change-management challenges will be significant in settings where clinicians are already skeptical of AI or where alert fatigue from other tools has created resistance. Leadership buy-in from the CMO, CMIO, and departmental chiefs is non-negotiable for successful adoption.

Onboarding timelines for enterprise AI tools in healthcare typically span three to six months from contract signature to full production deployment. This includes vendor-led configuration, IT infrastructure provisioning, pilot testing with a small clinician cohort, feedback loops, and gradual rollout. Organizations with mature AI governance frameworks and prior experience deploying ambient scribes or clinical decision support will move faster. Those without dedicated AI committees or IT staff experienced in healthcare-AI integrations should budget for longer timelines and higher internal resource costs.

Pricing realities

Corti's pricing model is enterprise-only, with no published per-seat costs or tiered plans. The vendor lists a single 'Enterprise' tier at zero disclosed cost, signaling that pricing is negotiated case-by-case based on organization size, call volume, or clinician count. This is standard for healthcare AI vendors targeting large health systems, but it creates a high barrier for smaller organizations and eliminates price-based competition during procurement. Buyers should request detailed quotes that break out per-seat annual fees, per-API-call usage costs if applicable, implementation fees, training costs, and ongoing support charges.

Hidden costs are likely. Ambient documentation and real-time decision-support tools often charge separately for: EHR integration services, custom workflow configuration, annual compliance audits, and premium support tiers for 24/7 uptime guarantees. If Corti operates on a usage-based model (per encounter or per minute of processed audio), costs can scale unpredictably with patient volume. Buyers should model worst-case cost scenarios based on peak-season encounter volumes and confirm whether the contract includes hard spending caps or volume discounts at defined thresholds.

ROI math is speculative without published time-savings data. Ambient scribes typically save clinicians 30 to 60 minutes per day in documentation time, translating to one to two additional patient slots or earlier end-of-shift times. If Corti delivers comparable documentation relief plus triage accuracy improvements that reduce ED revisits or missed diagnoses, the ROI case strengthens. However, without named case studies showing reduced length-of-stay, lower malpractice claims, or measurable throughput gains, buyers must treat vendor ROI projections as aspirational. Demand pilot data from your own organization before committing to multi-year contracts.

Compliance + integration depth

Corti's compliance posture is unclear from public materials. The vendor operates in Europe and markets to healthcare organizations, which implies GDPR compliance and likely ISO 27001 or equivalent information-security certifications. However, US buyers must independently verify HIPAA compliance, SOC 2 Type II attestation, and HITRUST certification before signing a BAA. The absence of these certifications in vendor marketing materials is a red flag; compliant vendors typically advertise security postures prominently. Procurement teams should request current audit reports, BAA templates, and evidence of third-party penetration testing before pilot deployment.

FDA clearance status is also ambiguous. If Corti is marketed as a diagnostic aid that influences triage decisions, it may fall under FDA regulation as a Software as a Medical Device (SaMD). The vendor's website positioning suggests clinical decision support, which would trigger SaMD review unless the tool qualifies for the Clinical Decision Support Software exemption under 21st Century Cures Act provisions. Buyers should ask the vendor directly whether Corti has received FDA 510(k) clearance, De Novo classification, or operates under the CDS exemption. Deploying an uncleared device marketed for clinical use creates institutional liability.

EHR integration depth is a make-or-break factor. Real-time decision support is only valuable if it surfaces alerts within the clinician's existing workflow, not in a separate browser tab or standalone app. Corti must integrate at the encounter level, either embedded in the EHR's telehealth module or via API calls that push alerts directly into the clinician's active patient chart. Buyers should confirm which EHR vendors are supported, whether integration is read-only (passive data pull) or bi-directional (write-back of notes and alerts), and what HL7 or FHIR standards are leveraged. Epic and Cerner integrations are baseline expectations for US health systems; anything less limits addressable market.

Vendor stability + roadmap

Corti's vendor stability is difficult to assess from public disclosures. The company is headquartered in Denmark and has operated since at least 2016 based on domain registration and early press mentions. Funding history, revenue scale, and customer count are not disclosed in indexed materials. Buyers should request customer references, ideally from US health systems or large European hospital networks, to validate that the vendor has successfully deployed at scale and maintained those deployments over multi-year contracts. Absence of named references is a red flag for any enterprise software vendor.

Leadership and acquisition risk are unknowns. Healthcare AI vendors frequently get acquired by EHR giants, private-equity-backed health IT consolidators, or larger AI platform companies. If Corti is venture-backed and has not disclosed recent funding rounds, financial sustainability may be a concern. Buyers should ask about the vendor's capitalization, burn rate, and path to profitability during procurement. Organizations entering multi-year contracts with early-stage vendors should negotiate clear exit terms, including data portability guarantees and contractual protections if the vendor is acquired or ceases operations.

Roadmap transparency is minimal. The vendor's public materials emphasize real-time triage and ambient documentation but do not outline planned feature expansions, specialty-specific modules, or EHR partnership announcements. Buyers evaluating Corti should ask about the vendor's product roadmap for the next 12 to 24 months, including plans for FDA clearance if not already obtained, expansion into new clinical specialties, and integration partnerships with major EHR vendors. Without a clear roadmap, buyers risk investing in a feature set that stagnates or diverges from organizational needs.

How it compares

Corti competes directly with Abridge, Nuance DAX Copilot, and Suki in the ambient documentation space, but differentiates by emphasizing real-time triage intelligence rather than pure note generation. Abridge focuses on specialty-specific templates and post-encounter summarization, with strong Epic integration and a growing evidence base in outpatient medicine. Nuance DAX Copilot is the incumbent, backed by Microsoft and deeply integrated into Epic and Oracle Health (formerly Cerner), with transparent pricing starting around $150 per clinician per month. Suki offers similar ambient scribe functionality with a mobile-first design and per-encounter pricing, appealing to smaller practices. None of these competitors advertise real-time clinical decision support as a core feature, which is Corti's stated differentiator.

For triage-specific workflows, Corti competes with K Health's AI triage platform, Buoy Health's symptom checker, and traditional nurse triage protocols augmented by Epic's embedded decision trees. K Health and Buoy are consumer-facing tools that patients use before contacting a provider, whereas Corti operates during the clinician-patient encounter itself. This makes Corti more analogous to UpToC or DynaMed in-encounter references, but with AI-driven real-time alerts rather than passive lookup. The competitive edge depends entirely on alert accuracy and false-positive rates, which cannot be assessed without published validation studies.

If triage accuracy is Corti's selling point, buyers should benchmark it against Isabel Healthcare and VisualDx, both of which offer differential-diagnosis support with longer track records and peer-reviewed validation. Isabel is used in emergency departments and outpatient settings to reduce diagnostic error, with published studies showing improved diagnostic accuracy when clinicians used the tool. VisualDx focuses on dermatology and visual diagnosis, with extensive image libraries and evidence in medical education settings. Corti wins if it delivers Isabel-level diagnostic support plus ambient documentation in one platform, but that claim requires validation buyers do not yet have access to.

Price comparison is impossible without Corti's published rates. Nuance DAX Copilot and Suki both publish starting prices or offer transparent quotes within one sales call. Abridge's pricing is also available upon request with clear per-seat tiers. Corti's enterprise-only model with zero disclosed pricing eliminates it from consideration for any buyer conducting apples-to-apples cost analysis. Until the vendor publishes at least a ballpark per-seat annual cost, smaller organizations should default to competitors with transparent pricing.

What clinicians say

Clinician sentiment data for Corti is absent from indexed sources. Searches across Reddit's r/medicine, r/Residency, and r/EMSProviders yielded zero mentions of the tool. Doximity and SERMO discussions similarly contain no indexed references to Corti. This absence suggests either very limited adoption in US clinician communities, or that early adopters have not yet shared experiences in public forums. For a tool marketed since at least 2016, the lack of organic clinician discussion is notable and suggests the product may still be in pilot or limited-release phases rather than widespread deployment.

The absence of clinician feedback creates a significant information gap for buyers. Peer discussions on Reddit and Doximity have proven to be early indicators of ambient-scribe satisfaction, alert-fatigue issues, and workflow friction for tools like Nuance DAX and Abridge. Without this organic feedback, procurement teams cannot assess training burden, false-alert frequency, or whether clinicians perceive Corti as helpful or intrusive. Buyers should request direct access to pilot users at reference sites and conduct their own focus groups with clinicians during proof-of-concept phases, rather than relying solely on vendor-curated testimonials.

If Corti enters wider US deployment, expect clinician sentiment to surface within six to twelve months in physician forums. Early feedback will likely focus on alert accuracy, integration smoothness with existing EHR workflows, and whether the real-time triage recommendations align with clinical judgment. Buyers considering Corti today should plan to revisit clinician sentiment in 2027, once a larger user base has accumulated enough experience to generate organic discussion.

What the literature says

Peer-reviewed literature evaluating Corti is nonexistent. A PubMed search for 'Corti' returned five citations, all of which pertain to auditory medicine: cisplatin-induced ototoxicity studies and hereditary hearing loss gene therapy. The term 'Corti' in these papers refers to the organ of Corti in the inner ear, not the AI clinical decision-support tool. This complete absence of indexed studies means no independent validation of the vendor's diagnostic accuracy claims, no published data on false-positive or false-negative rates, no clinician workflow studies, and no outcomes research linking Corti use to improved patient safety or reduced diagnostic delays.

The evidence gap is disqualifying for any organization subject to regulatory or accreditation requirements that mandate peer-reviewed validation for AI clinical decision support. The Joint Commission, CMS, and state medical boards increasingly expect health systems to document due diligence when deploying AI tools that influence clinical decisions. Without published studies, buyers cannot cite independent evidence of safety or efficacy in their AI governance submissions. This places Corti in the high-risk category for early-stage tools that require pilot testing under IRB oversight and contractual liability protections until validation studies emerge.

Vendors operating in the clinical AI space for five-plus years without published validation studies raise sustainability questions. Peer-reviewed publication is a standard milestone for healthcare AI companies seeking credibility and market expansion. The absence of studies may indicate the vendor has not prioritized academic partnerships, has not achieved sufficient deployment scale to generate publishable datasets, or has encountered negative results that were not submitted for publication. Buyers should ask the vendor directly whether validation studies are planned, in progress, or have been submitted to peer-reviewed journals, and request access to any preprint or conference abstracts if formal publications are pending.

Who it's for

Corti is best suited for large health systems with mature AI governance frameworks, dedicated IT support for complex integrations, and budget flexibility to pilot unproven tools. Specifically, emergency-medicine departments, 911 call centers, and telehealth triage lines operated by integrated delivery networks or accountable-care organizations may find value in Corti's real-time triage positioning, provided they treat the deployment as a research pilot rather than a validated clinical tool. CMIOs and IT leaders at these organizations should have experience deploying ambient scribes or clinical decision-support tools, established workflows for monitoring AI alert performance, and contractual leverage to negotiate liability protections and pilot exit terms.

Corti is not appropriate for solo practitioners, small group practices, community hospitals, or any organization lacking dedicated AI oversight. The absence of peer-reviewed validation, opaque pricing, and missing clinician sentiment data make this a high-risk adoption for resource-constrained settings. Even well-resourced organizations should hesitate unless they can dedicate internal resources to validating alert accuracy, monitoring false-positive rates, and conducting their own outcomes research during a controlled pilot. If your organization does not have IRB capacity or dedicated quality-improvement staff to oversee AI pilots, Corti is premature.

Specialty fit is unclear. The vendor's marketing emphasizes emergency and triage use cases, but whether Corti performs equally well in primary care, urgent care, or specialty telehealth is unknown. Organizations seeking ambient documentation for routine outpatient visits should default to proven competitors like Nuance DAX, Abridge, or Suki, which have published pricing, broader EHR integrations, and emerging evidence bases. Corti may differentiate in high-acuity settings where real-time alerts matter, but that differentiation requires validation buyers do not yet have.

The verdict

Corti earns a provisional rating: promising concept, insufficient evidence, suitable only for early-adopter pilots in well-resourced health systems. The tool's real-time triage intelligence layered onto ambient documentation is a compelling value proposition if it performs as advertised, but the absence of peer-reviewed validation, transparent pricing, and organic clinician feedback creates decision risk that most organizations cannot absorb. Buyers should treat Corti as an experimental tool requiring pilot testing under IRB oversight, contractual liability protections, and internal validation of alert accuracy before moving to production deployment.

If your organization already has mature AI governance, experienced IT staff, and budget flexibility: request a proof-of-concept with Corti and two competing ambient scribes (Nuance DAX, Abridge). Run parallel pilots in a single department for three to six months, measure documentation time savings, alert accuracy, false-positive rates, and clinician satisfaction. Publish your findings internally and share them with the vendor and broader healthcare AI community. Early adopters willing to conduct rigorous validation and share learnings provide essential public goods that de-risk later adoption by smaller organizations.

If your organization lacks dedicated AI oversight, has limited IT resources, or requires transparent pricing for budget planning: skip Corti until the vendor publishes peer-reviewed validation studies, transparent per-seat pricing, and named hospital references. Default to competitors with stronger evidence bases and clearer go-to-market strategies. Revisit Corti in 2027 if validation studies emerge and clinician sentiment surfaces in professional forums. The healthcare AI market moves quickly; waiting 12 to 24 months for stronger evidence is a defensible procurement strategy when early adoption carries institutional risk without proportional patient-safety evidence.